
BPC-157 FDA status in 2026: Compounding ban explained

As of February 15, 2026, BPC-157 is not an FDA-approved drug, and it appears on the FDA’s Section 503A “Category 2” bulk drug substances list.[2] In practice, that listing is a major reason routine 503A compounding and dispensing of BPC-157 is generally not permitted, and many licensed compounding pharmacies will not dispense it for routine ...













